In the past four years, three novel oral anticoagulant (NOAC) medications have become available: apixaban (Eliquis®), dabigatran (Pradaxa®), and rivaroxaban (Xarelto®). A fourth NOAC, edoxaban (Savaysa™), has been submitted for approval by the US Food and Drug Administration (FDA).
Although it is exciting to have so many alternatives to warfarin, the appropriate use of these medications is essential. There are no direct comparison data for these drugs, but we can draw some inferences from the major NOAC trials.
© 2014
WebMD, LLC
Cite this: Know Your NOACs - Medscape - Sep 29, 2014.
Comments